Curis Inc (NAS:CRIS)

$ 7.96 0.16 (2.05%) Market Cap: 46.92 Mil Enterprise Value: 8.68 Mil PE Ratio: 0 PB Ratio: 4.96 GF Score: 63/100

Q1 2024 Curis Inc Earnings Call Transcript
May 07, 2024

$16.2 (+0.19%)

Earnings
Q4 2023 Curis Inc Earnings Call Transcript
Feb 08, 2024

$10.65 (+13.42%)

Earnings
Q3 2023 Curis Inc Earnings Call Transcript
Nov 02, 2023

$4.51 (-4.25%)

Earnings
Q2 2023 Curis Inc Earnings Call Transcript
Aug 03, 2023

$15.42 (-2.98%)

Earnings
Q1 2023 Curis Inc Earnings Call Transcript
May 04, 2023

$16.76 (+3.48%)

Earnings
Q4 2022 Curis Inc Earnings Call Transcript
Mar 13, 2023

$11.51 (-8.40%)

Earnings
Curis Inc to Discuss Updated Emavusertib Clinical Data Call Transcript
Dec 12, 2022
Q3 2022 Curis Inc Earnings Call Transcript
Nov 09, 2022

$14.44 (-7.44%)

Earnings
Q2 2022 Curis Inc Earnings Call Transcript
Aug 04, 2022

$19.78 (+0.91%)

Earnings
Q1 2022 Curis Inc Earnings Call Transcript
May 05, 2022

$18.2 (-9.00%)

Earnings
Curis Inc at Needham Healthcare Conference (Virtual) - On-Demand Transcript
Apr 12, 2022
Q4 2021 Curis Inc Earnings Call Transcript
Feb 24, 2022

$63.4 (+8.19%)

Earnings
Curis Inc to Discuss Positive Updated Clinical Data on Phase 1/2 Monotherapy Study of CA-4948 and Initial Clinical Data from Phase 1 Study of CI-8993 Call Transcript
Jan 06, 2022
Q3 2021 Curis Inc Earnings Call Transcript
Nov 09, 2021

$114.4 (-4.83%)

Earnings
Curis Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 08, 2021
Curis Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 30, 2021
Curis Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 10, 2021
Q2 2021 Curis Inc Earnings Call Transcript
Aug 03, 2021

$139.8 (-9.46%)

Earnings
Curis Inc to Discuss Updated Clinical Data for CA-4948 in AML/MDS Presented at EHA Virtual Congress Transcript
Jun 11, 2021
Curis Inc Annual Shareholders Meeting Transcript
May 27, 2021
Q1 2021 Curis Inc Earnings Call Transcript
May 12, 2021

$325.4 (+65.51%)

Earnings
Q4 2020 Curis Inc Earnings Call Transcript
Mar 16, 2021

$211 (-4.26%)

Earnings
Curis Inc at H C Wainwright Global Life Sciences Conference (Virtual) - Pre-recorded Transcript
Mar 09, 2021
Curis Inc Virtual KOL Event - Reviewing CA-4948 Clinical Data in NHL & AML/MDS Transcript
Dec 08, 2020
Q3 2020 Curis Inc Earnings Call Transcript
Nov 10, 2020

$22.8 (+5.56%)

Earnings
Q2 2020 Curis Inc Earnings Call Transcript
Aug 04, 2020

$26.4 (+10.92%)

Earnings
Curis Inc Annual Shareholders Meeting Transcript
Jun 04, 2020
Q1 2020 Curis Inc Earnings Call Transcript
May 12, 2020

$17.51 (+1.70%)

Earnings
Curis Inc at Needham Healthcare Conference Transcript
Apr 14, 2020
Q4 2019 Curis Inc Earnings Call Transcript
Mar 19, 2020

$14.73 (+1.94%)

Earnings
Curis Inc Corporate Call Transcript
Dec 06, 2019
Q3 2019 Curis Inc Earnings Call Transcript
Nov 05, 2019

$39 (-19.75%)

Earnings
Q2 2019 Curis Inc Earnings Call Transcript
Aug 06, 2019

$46.4 (+0.87%)

Earnings
Q1 2019 Curis Inc Earnings Call Transcript
May 14, 2019

$38.2 (+3.24%)

Earnings
Q4 2018 Curis Inc Earnings Call Transcript
Mar 26, 2019

$40.2 (+6.35%)

Earnings
Curis Inc at Cowen Health Care Conference Transcript
Mar 13, 2019

Curis Inc at Needham Healthcare Conference Transcript

Apr 14, 2020 / 04:00PM GMT

Release Date Price: $14 (+4.48%)

Transcript

James Dentzer

Curis, Inc. - President & CEO

Good afternoon and welcome to the Needham Healthcare Conference for 2020. This is a virtual conference and I am Jim Dentzer, CEO of Curis. Curis' mission is to relentlessly develop innovative and differentiated therapeutics that improve the lives of cancer patients. And we do that by selecting the right targets, designing the right drugs and studying the right patients.

This leads us to a unique place in biotech where we are looking at novel first-in-class cancer drugs that we believe have significant potential in areas of unmet patient need. We are targeting blockbusters.

There are three drugs that meet that filter in our pipeline. The first one is CA-4948, the first-in-class inhibitor of IRAK4 in oncology. The second is CI-8993, a first in class antagonist, a monoclonal antibody targeting VISTA. And Fimepinostat, our first-in-class suppressor of MYC.

Over the last three years Curis has evolved steadily through the regulatory planning stage to clinical execution, and in 2020 we are expanding and reporting out data on 4948 in

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.